Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corp (NQ: ADPT )

9.630 +0.150 (+1.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 798,954
Open 9.420
Bid (Size) 8.910 (1)
Ask (Size) 10.27 (1)
Prev. Close 9.480
Today's Range 9.160 - 9.680
52wk Range 5.955 - 17.79
Shares Outstanding 143,012,157
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
From Adaptive Biotechnologies
Via Globe NewsWire
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via Globe NewsWire

Performance

YTD
+23.46%
+23.46%
1 Month
+11.20%
+11.20%
3 Month
+23.78%
+23.78%
6 Month
-14.09%
-14.09%
1 Year
-40.85%
-40.85%

More News

Read More
Nike, FedEx And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Looking Into Adaptive Biotechnologies's Return On Capital Employed
Via Benzinga
Expert Ratings for Adaptive Biotechnologies
Via Benzinga
Adaptive Biotechnologies Earnings Perspective: Return On Capital Employed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
What To Know About Piper Sandler's Upgrade of Adaptive Biotechnologies
Via Benzinga
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
From Adaptive Biotechnologies
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
Via Benzinga
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
From Adaptive Biotechnologies
Via Globe NewsWire
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
From Adaptive Biotechnologies
Via Globe NewsWire
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
From Adaptive Biotechnologies
Via Globe NewsWire
New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results
From Adaptive Biotechnologies
Via Globe NewsWire
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
5 Top Stocks Cathie Wood Is Buying This Week
Via InvestorPlace
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
From Adaptive Biotechnologies
Via Globe NewsWire
General Electric To Surge Around 27%? Plus This Analyst Predicts $44 For General Motors
Via Benzinga
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
From Adaptive Biotechnologies
Via Globe NewsWire
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022
From Adaptive Biotechnologies
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Via Benzinga
Adaptive Biotechnologies: Q2 Earnings Insights
Via Benzinga
Earnings Outlook For Adaptive Biotechnologies
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.